Lupin Ltd.'s shares gained after the U.S. health regulator gave its final nod for two of its drugs to be marketed in that country.
The pharmaceutical giant received final approval to market its generic version of Braintree Laboratories' Suprep Bowel prep Kit tablets. The drug is used for cleansing the colon, in preparation for colonoscopy in adults, the company said in a statement to the exchanges. Suprep reported annual sales of $207.2 million (Rs 1,382.8 crore) as of year-ended December 2016.
The other approval came in for Lupin's Oxycodone and Acetaminophen Tablets, a generic version of Vintage Pharmaceutical LLC's Percocet tablets. Percocet is used to treat moderate to severe pain and reported sales of $838.7 million (Rs 5,597.3) at the end of 2016, Lupin said in a separate statement.
The company will start promoting both the products shortly, it added.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
